Levaquin Label Update

The FDA updated the Levaquin label last week.

 June 28, 2019, the FDA updated the Levaquin label MEDICATION GUIDE which is the information given to patients.

The FDA added more psychiatric adverse event warnings to the MEDICATION GUIDE including:

  • Feeling agitated
  • Reduced awareness of surroundings
  • Memory problems
  • False or strange thoughts or beliefs (delusions)

The June 28, 2019 MEDICATION GUIDE also now states that “Tendon problems may be permanent.”



David experienced an adverse event to the the fluoroquinolone Levaquin in 2007 at age 46. Prior to, he was a healthy law enforcement official. Now, disabled with drug induced mitochondrial disease/dysfunction, he is an FQ patient safety advocate, citizen scientist, FQ researcher, author, and commentator. He has contributed to case studies and published academic papers on the FQ’s in the BMJ, European Journal of Medicine, The Journal of Community and Supportive Oncology, Oxford Academic Clinical infectious Diseases, and contributed data to many more outlets.

3 Responses

  1. Geoffrey Comer says:

    Hi How can I get a copy of this update? I have searched the FDA site but cannot find it. We live in the UK and my wife was floxed in Spain 9 years ago. Most doctors here don’t recognise the warnings and we battle on. Your site is a tremendous help and support

  2. Joan M. Bauer says:

    I had a terrible time with it, spent some time in the hospital.

  3. Cw says:

    My chiropractor recently told me he was once prescribed Levaquin and all he could think of was driving his car off a bridge. This was quite awhile ago. He immediately called his doc who told him to stop taking it immediately. Wish other docs would have been as smart.

Leave a Reply

Your email address will not be published. Required fields are marked *

WordPress Anti Spam by WP-SpamShield